Development of hydroxy-based sphingosine kinase inhibitors and anti-inflammation in dextran sodium sulfate induced colitis in mice

Add time:07/13/2019    Source:sciencedirect.com

Sphingosine kinase (SphK)-catalyzed production of sphingosine-1-phosphate (S1P) regulates cell growth, survival and proliferation as well as inflammatory status in animals. In recent study we reported the N′-(3-(benzyloxy)benzylidene)-3,4,5-trihydroxybenzohydrazide scaffold as a potent SphK inhibitor. As a continuation of these efforts, 51 derivatives were synthesized and evaluated by SphK1/2 inhibitory activities for structure–activity relationship (SAR) study. Among them, 33 was identified as the most potent SphK inhibitor. Potency of 33 was also observed to efficiently decrease SphK1/2 expression in human colorectal cancer cells (HCT116) and significantly inhibit dextran sodium sulfate (DSS)-induced colitis as well as the decreased expression of interleukin (IL)-6 and cyclooxygenase-2 (COX-2) in mouse models. Collectively, 33 was validated as an effective SphK inhibitor, which can be served as anti-inflammatory agent to probably treat inflammatory bowel diseases in human.

We also recommend Trading Suppliers and Manufacturers of 2-(2-chlorobenzyl)guanidine sulfate (2:1) (cas 3458-33-1). Pls Click Website Link as below: cas 3458-33-1 suppliers

Prev:One-step aldehyde group transformation by using guanidine and aminoguanidine: Synthetic, structural and computational studies
Next:Substituted benzo[d]oxazol-2(3H)-one derivatives with preference for the σ1 binding site)